Does Rallies show Form 4 insider transactions for BCDA?

Yes. Rallies tracks BCDA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BCDA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BCDA. It does not provide personalized investment advice.

BCDA (BioCardia, Inc. Common Stock) Stock Analysis - Insider Trades

BioCardia, Inc. Common Stock (BCDA) is a publicly traded Healthcare sector company. As of May 21, 2026, BCDA trades at $0.96 with a market cap of $10.24M and a P/E ratio of -0.76. BCDA moved -2.22% today. Year to date, BCDA is -27.56%; over the trailing twelve months it is -53.06%. Its 52-week range spans $0.84 to $3.20. Analyst consensus is buy with an average price target of $15.50. Rallies surfaces BCDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BCDA stock inside the company?

Recent BCDA insider activity includes Altman Peter bought 5.70K, Altman Peter bought 5.10K, Altman Peter bought 5.00K, Altman Peter bought 400, and Altman Peter bought 600. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BCDA Key Metrics

Key financial metrics for BCDA
Metric	Value
Price	$0.96
Market Cap	$10.24M
P/E Ratio	-0.76
EPS	$-1.23
Dividend Yield	0.00%
52-Week High	$3.20
52-Week Low	$0.84
Volume	15.54K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-8.23M
Gross Margin	0.00%

Recent BCDA Insider Trades

Altman Peter bought 5.70K (~$5.24K) on May 18, 2026.
Altman Peter bought 5.10K (~$5.20K) on May 15, 2026.
Altman Peter bought 5.00K (~$5.55K) on Apr 29, 2026.
Altman Peter bought 400 (~$492) on Apr 21, 2026.
Altman Peter bought 600 (~$738) on Apr 20, 2026.

Latest BCDA News

BioCardia Earns FDA Breakthrough Designation, Secures $20K Medicare Reimbursement — May 16, 2026
BioCardia Targets 20,000 Japanese Patients with CardiAMP Shonin Submission, FDA Endorses Helix Pathway — May 15, 2026
FDA Agrees Two Clearance Pathways for BioCardia's Helix Catheter, No Safety Concerns — May 8, 2026
Japan’s PMDA Finds CardiAMP Cell Therapy Data Sufficient for Market Clearance — Apr 20, 2026
BioCardia Files Q2 FDA Meeting Request for Accelerated Approval of CardiAMP in 125-Patient Trial — Apr 2, 2026

BCDA Analyst Consensus

2 analysts cover BCDA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.50.

Common questions about BCDA

Who is trading BCDA stock inside the company?: Recent BCDA insider activity includes Altman Peter bought 5.70K, Altman Peter bought 5.10K, Altman Peter bought 5.00K, Altman Peter bought 400, and Altman Peter bought 600. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BCDA?: Yes. Rallies tracks BCDA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BCDA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BCDA. It does not provide personalized investment advice.